PRAME and neoplasm: By combining mRNA-seq datasets of healthy and tumor tissues, we selected preferentially expressed antigen of melanoma (PRAME), CCCTC-binding factor (CTCFL), and Claudin-6 (CLDN6) as TAAs with high expression in ovarian cancer and at least 20-fold lower expression in all healthy tissues of risk.